Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Down 43.7% in August

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totaling 178,126 shares, a decrease of 43.7% from the August 15th total of 316,392 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily volume of 691,114 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Ratings Changes

MBRX has been the topic of a number of analyst reports. HC Wainwright cut their price objective on shares of Moleculin Biotech to $3.00 and set a “buy” rating on the stock in a report on Friday, August 28th. Wall Street Zen upgraded shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $3.00.

Moleculin Biotech Stock Up 8.4%

Shares of MBRX opened at $0.78 on Tuesday. Moleculin Biotech has a twelve month low of $0.16 and a twelve month high of $15.75. The stock has a market cap of $15.10 million, a PE ratio of -0.11 and a beta of 1.92. The business’s 50-day moving average price is $1.14 and its 200-day moving average price is $2.00.

Moleculin Biotech (NASDAQ:MBRX) last released its earnings results on Thursday, August 13th. The company reported ($1.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.15. Analysts expect that Moleculin Biotech will post -2.37 earnings per share for the current fiscal year.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.